Replies to post #20670 on ViaDerma Inc (VDRM)

[Mistral]

That's Otiko's defense as presented in writing to shareholders. There is so much written evidence in Otiko's news releases and financials, along with the website claims that Diabecline was their Lead Product in February 2017, that can be used against him.

Anyone can call the USPTO, as I did, and learn there is an active dispute, no Final Action, or simply look at the Transaction History displayed below.

Keough ABANDONED patents, forfeiting IP and contracts. Addendum signed between Phillips and Otiko. NOTHING TO WORRY ABOUT IMO. $$$ Coming by end of year